about
National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.Clinical, biochemical and pathological profiles of 5464 Egyptian chronic hepatitis C-infected patients.The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysisAssessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patientsAccurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients.Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup.Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infectionSingle nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children.Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4.Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients.Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients.IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma.Fibroscan of chronic HCV patients coinfected with schistosomiasis.Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response.Comparison of Machine Learning Approaches for Prediction of Advanced Liver Fibrosis in Chronic Hepatitis C Patients.Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.Study of predictive value of pediatric risk of mortality (PRISM) score in children with end stage liver disease and fulminant hepatic failure.The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patientsEfficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experienceEvaluation of acoustic radiation force impulse (ARFI) elastography as non-invasive diagnostic tool in living donor liver transplantationSustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infectionHigh SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter studyLiver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients
P50
Q30238676-00D20866-8FE0-4CBE-97A6-5C9ABD1826F5Q30577014-F45073AC-9213-43E1-B198-1ECF8FCA3791Q33413981-95456883-B658-4830-B1AF-9C6835592977Q34996891-85192EC7-631D-4A12-A7DD-793B49D9B14CQ35397221-2BD0C7C3-04E8-4462-B75C-F9CF150D9541Q36414090-E02D2DDF-5CBD-4A7D-97C4-A4F7C8C87D60Q36530883-B635A1DD-0BD1-47C9-A42D-CCD6DFE1F123Q36546657-4BE40273-EFC6-4E85-AA00-DE5BC7699B4BQ36819615-0B5E755B-D938-48E7-A8CB-CE7638E7466CQ37222778-7D359247-F19A-4314-AC63-D1C53D31865DQ38984116-E32CAB39-6AC4-4D46-9988-59ED83051CDBQ38988445-1232FB54-1BF7-4820-8EE2-55C1F55B46EEQ38990813-35474C7A-D334-437A-8B2D-0487F29F4E22Q38991020-C62832C0-F5C9-44B0-A53B-4A4A10270364Q38992672-0EC0A60B-1B0E-437D-B4FE-5FBE015F59F2Q38995251-5D5A510B-9496-4165-AF00-F0D59B043601Q39133311-57CE2C44-A2D5-4F4B-938C-F0C1074269A5Q39382381-99322D29-8D55-4C6E-9E83-F40E56C701F8Q39952246-4E72BB49-5998-4FF7-B2B6-D5AFF4DD4326Q40344794-D21FB2AB-77CA-4CA5-8258-82669F5787FBQ40926297-2C4E60C7-FAE6-4078-9AA2-302EB7CCFE8DQ40940566-2BBCCB6F-0CC8-4618-BE50-DBFB55459F3FQ41921235-3C1BA037-5AAC-4C9C-9DA4-583C1D5A718DQ42256926-298162F2-283B-44F6-BEB0-B009D6075D3FQ42256932-5DFE5A7A-6B54-4002-B74F-3569147291D4Q43036965-470873F0-AABD-44F9-86EF-0C2D20760465Q45947777-AA0233DC-CBDC-4165-AF55-58852D6F425FQ46445455-37DD84A4-BC36-47A9-9223-64DFB26B6204Q47338069-90065FBE-8E2B-447F-BD66-C333BC0AACA9Q47550461-B4BF6177-9632-4302-A4A8-C34B81E74F4FQ51747608-270043DB-5BD2-4588-8F5D-34472102E64CQ53700836-B4C3355C-71B6-4672-8C39-DEE6C91390EFQ53732217-DD2B35C0-A477-4EF3-9703-0925183BDB8BQ59349009-4638EDE7-205F-4786-9E87-BC79AB026AF2Q90482685-351AE2CE-0ECB-474D-BFB8-0FF8693C2E6CQ91254758-F3D5DC47-D143-4FF6-8912-8980D347F674Q92565125-D7EFDA24-FCE3-4FE8-BC8D-2B70EF3A0DDBQ92584275-5D9E5E92-F965-4589-B565-FC6C60DC7E98Q92655293-0552F4A2-AB93-4120-8CAF-E265FD1055BE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wafaa El-Akel
@ast
Wafaa El-Akel
@en
Wafaa El-Akel
@es
Wafaa El-Akel
@nl
type
label
Wafaa El-Akel
@ast
Wafaa El-Akel
@en
Wafaa El-Akel
@es
Wafaa El-Akel
@nl
prefLabel
Wafaa El-Akel
@ast
Wafaa El-Akel
@en
Wafaa El-Akel
@es
Wafaa El-Akel
@nl
P106
P108
P1153
16678325000
P31
P496
0000-0002-0055-2230